The review found no eligible studies for this question.
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 6 weeks compared with placebo (high certainty).
Low dose naltrexone showed no clear difference in induction of clinical remission CDAI < 150 compared with placebo (low certainty).
Low dose naltrexone may leads to higher induction of 70‐point clinical response CDAI compared with placebo (low certainty).
Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
Low dose naltrexone showed no clear difference in sleep disturbance (adverse event) compared with placebo (low certainty).
Low dose naltrexone showed no clear difference in withdrawals due to adverse outcomes compared with placebo (low certainty).
Usual care may leads to lower relapse at 12, 18 or 24 months compared with immunosuppressive withdrawal after monotherapy (low certainty).
It is very uncertain whether usual care changes new CD‐related complications compared with immunosuppressive withdrawal after monotherapy (very low certainty).
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after monotherapy (low certainty).
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
Usual care showed no clear difference in relapse at 12 or 24 months compared with immunosuppressive withdrawal after combination therapy (low certainty).
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after combination therapy (low certainty).